Posted 17 September 2014
By Meredith Brown-Tuttle, RAC
"Orphan drugs" are product intended for use in the treatment of a "rare" disease—those diseases that occur infrequently or rarely in the general population of a specific location.
Share this article:
Categories: Biologics and biotechnology, Drugs, Features, US, Canada, Europe, Asia, Latin America and Caribbean, Middle East, Oceania, FDA, EMA, EC, PMDA, TGA
Tags: Orphan Drugs, Orphan Disease, Orphan Drug Act, Ultra-Orphan Diseases, Orphan Drug Regulations